anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Individuals diagnosed with connective tissue disorders (CTD) are known to be predisposed to incisional hernia formation. However, there is a scarcity of data on outcomes for these patients undergoing hernia repair. We sought to describe our outcomes in performing abdominal wall reconstructions in these complex patients.
METHODS: Adult patients with CTD undergoing open, elective, posterior component separation with permanent synthetic mesh at our institution from January 2018 to October 2022 were queried from a prospectively collected database in the Abdominal Core Health Quality Collaborative. We evaluated 30-day wound morbidity, perioperative complications, long-term hernia recurrence, and patient-reported quality of life.
RESULTS: Twelve patients were identified. Connective tissue disorders included Marfan's n = 7 (58.3%), Loeys-Dietz syndrome n = 2 (16.7%), Systemic Lupus Erythematosus n = 2 (16.7%), and Scleroderma n = 1 (8.3%). Prior incisions included three midline laparotomies and nine thoracoabdominal, mean hernia width measured 14 cm, and 9 were recurrent hernias. Surgical site occurrences (SSOs) were observed in 25% of cases, and 16.7% necessitated procedural intervention. All twelve patients were available for long-term follow-up, with a mean of 34 (12-62) months. There were no instances of reoperation or mesh excision related to the TAR procedure. One patient developed a recurrence after having his mesh violated for repair of a new visceral aneurysm. Mean HerQLes scores at 1 year were 70 and 89 at ≥ 2 years; Mean scaled PROMIS scores were 30.7 at 1 year and 36.3 at ≥ 2 years.
CONCLUSION: Ventral hernia repair with TAR is feasible in patients with connective tissue disorder and can be a suitable alternative in patients with large complex hernias.
In the intensive care unit (ICU), sedation is used to improve comfort and tolerance during mechanical ventilation, invasive diagnostic and therapeutic interventions or nursing care. The most commonly used sedatives are intravenous benzodiazepines and propofol. These agents are associated with over-sedation in 40 to 60% of patients, which can lead to prolonged intubation, delirium and drug-induced hypotension. Volatile anesthetics are increasingly used for sedation in European and Canadian intensive care units that offer advantages of rapid drug on and off effects and clearance via pulmonary exhalation with no active metabolites. Delivery of volatile agents in the ICU can be simply performed using a small lightweight and portable anesthetic reflector so-called anesthesia conserving device. Compared with intravenous sedatives, volatile anesthetics may allow shorter time to extubation and can facilitate mental recovery.

In mechanically ventilated patients, a growing body of evidence suggests that the mechanical power (MP) plays an important role in the ventilator-induce lung injury (VILI) and prognosis in in both acute respiratory distress syndrome (ARDS) and non-ARDS patients. MP is the energy per unit time released to the respiratory system according to the tidal volume, PEEP, respiratory rate, and flow applied. In ARDS patients receiving invasive mechanical ventilation, high MP was associated an increased mortality. Moderate to deep sedation can inhibit the respiratory center and reduces the excessive respiratory drive, thereby reducing transpulmonary pressure and MP as well as probably reducing lung injury. The purpose of this study aims to investigate the effect of inhalation sedation on MP in mechanically ventilated patient admitted in the ICU. We hypothesize that MP in mechanically ventilated patients can be reduced by administering inhalational sedation.
PROBLEM TO BE SOLVED: To obtain a detergent composition containing a specific aliphatic acid taurine salt as an essential component, giving excellent foaming and quality of foam with a slight pH dependence of foaming without creak feeling, stretching feeling and also a malodor, and useful for a shampoo and a detergent for cloths, etc. SOLUTION: This detergent composition contains a compound expressed by the formula: R-COO<-> H3 N<+> -CH2 -CH2 -SO3 <-> X<+> [R is a 7-23C (un)saturated hydrocarbon group; X is an alkali metal such as sodium, potassium and lithium or an organic alkali such as triethanolamine, diethanolamine and lysine] (e.g. taurinesodium laurate or taurine triethanolamine laurate) as an essential component in an amount of, e.g. 0.5-90wt.%. The compound of the formula is obtained by, e.g. dissolving an 8-24C fatty acid at 80 deg.C, adding an aqueous solution of taurine and a prescribed alkali aqueous solution with separately stirring and reacting the resultant mixture.
The invention discloses application of dehydroevodiamine in preparing a medicine for treating acute gastritis, and relates to the field of biological medicines. Application of dehydroevodiamine in preparing medicine for treating acute gastritis is provided. Wherein, the dehydroevodiamine can obviously improve the MDA and SOD levels of the gastric mucosa of the mice with acute gastritis. Wherein, the dehydroevodiamine can obviously reduce the gastric mucosal ulcer index of the mouse. The medicine for treating acute gastritis comprises effective dose of dehydroevodiamine and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is a diluent, a disintegrant, a binder, a lubricant or a stabilizer. The invention has the following advantages: 1. dehydroevodiamine can significantly improve the levels of MDA and SOD of gastric mucosa of mice with acute gastritis; 2. wherein, the dehydroevodiamine can obviously reduce the gastric mucosal ulcer index of the mouse.
Secondary hyperparathyroidism is characterized by an elevation in parathyroid hormone (PTH) associated with inadequate levels of active vitamin D hormone. The source of vitamin D in the body is from synthesis in the skin as vitamin D 3and from dietary intake as either vitamin D 2or D 3. Both vitamin D 2and D 3require two sequential hydroxylations in the liver and the kidney to bind to and to activate the vitamin D receptor (VDR). The endogenous VDR activator, calcitriol [1,25(OH) 2D 3], is a hormone that binds to VDRs that are present in the parathyroid gland, intestine, kidney, and bone to maintain parathyroid function and calcium and phosphorus homeostasis, and to VDRs found in many other tissues, including prostate, endothelium and immune cells. VDR activation is essential for the proper formation and maintenance of normal bone. In the diseased kidney, the activation of vitamin D is diminished, resulting in a rise of PTH, subsequently leading to secondary hyperparathyroidism and disturbances in the calcium and phosphorus homeostasis. Decreased levels of 1,25(OH) 2D 3have been observed in early stages of chronic kidney disease. The decreased levels of 1,25(OH) 2D 3and resultant elevated PTH levels, both of which often precede abnormalities in serum calcium and phosphorus, affect bone turnover rate and may result in renal osteodystrophy.
Back strengthening exercises. The Group 2 (G2) will perform therapy including strengthning of back muscles on a Roman chair machine for flexion and extension of trunk with load progression from training volume for endurance and strength gains.
FIELD: medicine.SUBSTANCE: invention refers to surgical dentistry and maxillofacial surgery. For micropenny sclerotherapy of arteriovenous malformations of the maxillofacial region of the patient, a vascular malignancy of the maxillofacial region of the patient is detected in the position of the patient lying on his back or sitting in an armchair with the help of ultrasonic Dopplerography in the energy mode. Linear sensor is used with frequency of 5–10 MHz in real time. Localization and size of vascular malignancy are evaluated. Skin vascular border marking is applied on the skin. Further, after performing general anesthesia, under the ultrasound control using the linear sensor equipped with the Doppler blood flow analysis option with 5–10 MHz test frequency, the vascularised new growth is punctured by inserting the puncture needle and moving it into the vascular pedicle lumen until the blood drop appears in the puncture needle or in the sterile syringe filled with steroid saline. After that, without changing the position of the needle, a syringe is attached to it with a pre-prepared sclerosing micropenny composition (SMC). When the needle is brought out of the neoplasm of the new growth, the space of the SMC is filled. Herewith, the QMS is prepared before direct introduction into the cavity of the vascular malignancy by mixing the sclerosing preparation with air, carbon dioxide or a mixture of air and carbon dioxide at ratio of 1:3.5 to 1:4.5. Sclerosing agent used is 3 % lauro macrogol 400 or 3 % solution of 2-methyl-7 ethylun-decyl-4 sodium sulphate or 3 % sodium tetradecyl sulphate solution. Herewith, SMK is displaced from vascular neoplasm of blood and inner layer of vein - intima is dissolved. After micropenny scleroobliteration and extraction of puncture needle on maxillofacial area of patient is applied for 3–5 days as a compression bandage sterile plaster "compress" for pressing walls of vein to each other.EFFECT: method provides high clinical effectiveness with obtaining a stable therapeutic effect in the absence of paraesthesia, lymphorrhea and haematomas due to low traumatism of lymphatic pathways and nerve fibers, high cosmetic effect due to absence of scar formation.1 cl, 4 ex
The combination of DNA methylation analysis with histopathological and genetic features allows for a more accurate risk stratification and classification of meningiomas. Nevertheless, the implications of this classification for patients with grade 2 meningiomas, a particularly heterogeneous tumor entity, are only partially understood. We correlate the outcomes of histopathologically confirmed grade 2 meningioma with an integrated molecular-morphologic risk stratification and determine its clinical implications. Grade 2 meningioma patients treated at our institution were re-classified using an integrated risk stratification involving DNA methylation array-based data, copy number assessment and TERT promoter mutation analyses. Grade 2 meningioma cases according to the WHO 2021 criteria treated between 2007 and 2021 (n = 100) were retrospectively analyzed. The median clinical and radiographic follow-up periods were 59.8 and 54.4 months. A total of 38 recurrences and 17 deaths were observed. The local control rates of the entire cohort after 2-, 4-, and 6-years were 84.3%, 68.5%, and 50.8%, with a median local control time of 77.2 months. The distribution of the integrated risk groups were as follows: 31 low, 54 intermediate, and 15 high risk cases. In the multivariable Cox regression analysis, integrated risk groups were significantly associated with the risk of local recurrence (hazard ratio (HR) intermediate: 9.91, HR high-risk: 7.29, p < 0.01). Gross total resections decreased the risk of local tumor progression (HR gross total resection: 0.19, p < 0.01). The comparison of 1p status and integrated risk groups (low vs. intermediate/high) revealed nearly identical local control rates within their respective subgroups. In summary, only around 50% of WHO 2021 grade 2 meningiomas have an intermediate risk profile. Integrated molecular risk stratification is crucial to guide the management of patients with grade 2 tumors and should be routinely applied to avoid over- and undertreatment, especially concerning the use of adjuvant radiotherapy.
Adipose tissue dysfunction is a key feature of metabolic syndrome, which increases the risk of periodontitis, an inflammatory disease induced by bacteria that affects the gingiva and other components of periodontal tissue. Recent studies indicate that molecules from inflamed periodontal tissue contribute to adipose tissue dysfunction. However, the cellular mechanisms and interactions between adipose tissue and gingiva driving the progression of metabolic and periodontal conditions remain unclear. To address this, we developed a chimeric (mouse/human) co-culture tissue model (which identifies the origins of species-specific cytokines) to investigate these interactions. Using tissue-specific functional cells and immunocytes, we constructed equivalents of adipose tissue (ATE) and gingiva (GTE), co-cultivating them under inflammatory conditions induced by bacterial endotoxin, lipopolysaccharide (LPS). Our findings showed that exposure to LPS resulted in a notable reduction in lipid accumulation, GLUT4 expression, and adiponectin secretion in ATE, along with increased macrophage colonies forming around lipid droplets, as well as elevated levels of triglyceride, leptin, and IL-6. In GTE, LPS triggered significant inflammatory responses, characterized by increased macrophage accumulation, elevated COX-2 expression, and heightened secretion of inflammatory cytokines. LPS also reduced epithelial thickness and the expression of keratin 19 and collagen IV, indicating impaired barrier function and gingival integrity. Co-culturing ATE with GTE exacerbated these LPS-induced harmful effects in both tissues. In conclusion, our findings suggest that interplay between gingiva and adipose tissue can intensify the inflammatory and dysfunctional changes caused by LPS. This co-culture tissue model offers a valuable tool for future studies on periodontitis and metabolic syndrome.
This is a single arm study, all participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
Participants in this group will take part in the 20 session dog-assisted therapy. This therapy will be added to their usual daily living and therapies. They will be assessed before and after the 10 week program.
PROBLEM TO BE SOLVED: To obtain the subject liquid agent having suppressed precipitation and decomposition of amino acids in the liquid, giving little disagreeable taste and odor to enable easy administration and useful for foods and pharmaceuticals by adding caramel and a carbohydrate-based sweetener composed essentially exclusively of a sugar alcohol. SOLUTION: This agent contains (A) caramel and (B) a carbohydrate-based sweetener composed essentially exclusively of a sugar alcohol (e.g. xylitol and erythritol). The amount of the component A is 0.2-20 pts.wt. based on 1 pt.wt. of the amino acid and that of the component B is 10-30 wt.% based on the total liquid agent. The amount of carbohydrate sweetener other than the component B is <=1 wt.% based on the total liquid agent. The amino acids to be compounded to the liquid agent are preferably tryptophan, phenylalanine, etc. The pH of the agent is preferably adjusted to 3-6 with citric acid, etc.
The present invention relates to antimicrobial compositions and methods for their use. In particular, the compositions comprise a glycerolipid, such as Capmul MCM, Imwitor 742, or Imwitor 988, and an antimicrobial agent, wherein the glycerolipid potentiates the activity of the antimicrobial agent. Antimicrobial agents encompassed by the present invention include antibiotics, antiseptics, and antifungals. Antimicrobial compositions encompassed by the present invention can be used for the treatment or prevention of an infection, such as a bacterial or fungal infection, or for reducing the viability of a microorganism, such as a bacterium. The present invention also relates to methods for potentiating the activity of an antimicrobial agent, for reducing the dose of an antimicrobial agent required to treat or prevent an infection, or for increasing the potency of an antimicrobial agent required to treat or prevent an infection, by administering an antimicrobial composition described herein. Kits comprising the antimicrobial compositions are also encompassed by the present invention.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to cardiology, and relates normalisation of cardio-vascular system functional reactivity in case of arterial hypertension with metabolic syndrome. For this purpose evaluation of CVS functional reactivity state under psychoemotional load is performed by registration of systolic diastolic, mean dynamic pressure and heart beat rate (HBR). On the basis of said data functional reactivity index (FRI) is determined before and after the load by the formula: FRI=(APav.dyn.x HBR)100 (conv.unit). If FRI is higher than 20 conv.units complex treatment including individually composed hypocaloric diet, which is calculated by formula taking into account sex, age and body weight, reasonably dosed static and dynamic physical loads, as well as introduction of valsartan 80 mg 1 time in the morning and pioglitazone 30 mg 1 time in the morning during not less than 3 months. ^ EFFECT: said complex of medicinal and non-medicinal therapy in combination with empirically selected treatment duration ensure normalisation of CVS functional reactivity in said group of patients due to potentiation of therapeutic effect of certain components of medicinal complex. ^ 2 ex
The present invention relates to a hydrogel containing coenzyme Q10 and a cataplasm prepared by the hydrogel. The coenzyme Q10 of the present invention is prepared into nanoparticles, solid lipid nanoparticles, flexible nano-liposomes, nano-microemulsion, nano-micelles and the like. Especially that the flexible coenzyme Q10 nano-liposomes are preferably adopted in the hydrogel of the present invention. The coenzymes Q10 with various forms are adopted to prepare the hydrogel, the cataplasm prepared by the hydrogel, and other external application preparations or apparatuses. In the prior art, the coenzyme Q10 in the common external application preparation containing the coenzyme Q10 is easily oxidized and decomposed, and is preserved difficultly. With the present invention, the problems in the prior art are effectively solved; the skin penetration performance of the coenzyme Q10 is substantially increased. The hydrogel and the cataplasm prepared by the hydrogel can be applicable for dermal topical application and nursing of the coenzyme Q10, or percutaneous systematic administration of the coenzyme Q10, specifically for preparation into cosmetics, health products, or drugs and the like. The present invention further relates to a use of the coenzyme Q10 nano-preparation in preparation of the coenzyme Q10 hydrogel preparation.
EUS-FNA with ROSE is performed with a 22 or 25 gauge FNA needle. The sampled specimen is expressed into a glass slide with a stylet; then using another glass slide the sample is spread out to make smears on two slides. Each pair of slides is then numbered according to their respective needle passes. One slide is air dried and stained with modified Giemsa stain for ROSE, while the other slide is fixed in 95% ethanol and later coated with with Papanicolaou stain.
The limits of sensitivity of available analytical methodology precluded demonstration of bioequivalence between intramuscular and intravenous routes of administration.

###  Elimination    


In postoperative adults, pharmacokinetic studies have shown elimination half-lives ranging from 1.2 to 7.2 hours (mean 2.2 hours) after intravenous administration of 0.3 mg of buprenorphine. A single, ten-patient, pharmacokinetic study of doses of 3 mcg/kg in children (age 5 to 7 years) showed a high inter-patient variability, but suggests that the clearance of the drug may be higher in children than in adults. This is supported by at least one repeat-dose study in postoperative pain that showed an optimal inter-dose interval of 4 to 5 hours in pediatric patients as opposed to the recommended 6 to 8 hours in adults.

###  Metabolism    


Buprenorphine undergoes both N-dealkylation to norbuprenorphine and glucuronidation. The N-dealkylation pathway is mediated primarily by CYP3A4. Norbuprenorphine, the major metabolite, can further undergo glucuronidation. Its clearance is related to hepatic blood flow. Studies in patients anesthetized with 0.5% halothane have shown that this anesthetic decreases hepatic blood flow by about 30%.
Visceral fat accumulation is considered to be associated with a higher risk of chronic diseases. We investigated the effects of Bifidobacterium longum subsp. longum (B. longum) BB536 and Bifidobacterium breve (B. breve) MCC1274 on body composition, including visceral fat, in a randomized, parallel-group, placebo-controlled study. Participants were between 29 and 64 years of age and had a body mass index (BMI) of greater than 23 and less than 30. One hundred participants were randomly assigned to the probiotics group or placebo group. Participants were administered probiotic capsules containing 1 × 1010 colony-forming units (CFUs) of B. longum BB536 and 5 × 109 CFU of B. breve MCC1274 or placebo capsules without bifidobacteria for 16 weeks. In the probiotics group, abdominal visceral fat area, total abdominal fat area, and serum triglyceride levels were significantly decreased compared to those in the placebo group. Additionally, the increase in BMI observed in the placebo group was significantly suppressed in the probiotics group. This study showed that B. longum BB536 and B. breve MCC1274 reduced abdominal visceral fat and total fat levels in healthy normal and overweight adults, suggesting their beneficial effects on body composition.
INTRODUCTION: Obesity is associated with a plethora of health complications, including increased susceptibility to infections or decreased vaccine efficacy, partly due to dysregulated immune responses. Monocytes play a crucial role in innate immunity, yet their functional alterations in obesity remain poorly understood.
METHODS: Here, we employed proteomic and metabolomic analyses to investigate monocyte characteristics in individuals with overweight, obesity, impaired glucose tolerance (IGT), and type 2 diabetes (T2D), compared to lean donors.
RESULTS AND DISCUSSION: Our results revealed distinct molecular signatures in monocytes from individuals with obesity, with significant alterations in pathways related to metabolism, cellular migration, and phagocytosis. Moreover, LPS-induced activation of monocytes unveiled heightened metabolic reprogramming towards glycolysis in subjects with obesity accompanied by dysregulated cytokine responses and elevated oxidative stress. Additionally, monocytes from donors with obesity exhibited increased lipid droplet accumulation. These findings shed light on the immunometabolic dysregulation underlying obesity-associated immune dysfunction, highlighting potential targets for therapeutic intervention.
Following IRB approval and written consents, patients undergoing nephrectomy were randomized into 2 groups: standard 0.2% ropivacaine infusion (control) and 0.4% lidocaine infusion for TAP catheter. The TAP catheters were placed by the surgeons under direct vision at the end of surgery before wound closure. All subjects had a general anesthetic in accordance to the discretion of the anesthesiologist in the operating room. At the end of surgery, all patients received a patient-controlled analgesia (PCA) in recovery for 48 hours. The primary outcome was the total opioid consumption at the first 27 hours post-operatively. The secondary outcomes were the total opioid consumption at 4/12/24/36/48/60 hours after the initiation of local anesthetic infusion, the numerical rating scale (NRS) at rest and on movement at 4/12/24/36/48/60 hours after the initiation of the local anesthetic infusion, the incidence of nausea and vomiting, and adverse effects.

The sample size calculation for this non-inferiority trial is based on our previous retrospective study on TAP in nephrectomy patients. A sample of 80 patients is needed, using a power of 90% with the two-sided significance level of 5%. All parametric data will be analyzed using mean and standard deviation. Non-parametric data will be analyzed using median and interquartile range. Student's t-test or Mann-Whitney U test will be used to compare between groups.